Fundamentals-based quality & risk · not a recommendation
Glenmark Pharmaceuticals Ltd scores 57/100 (Watch) on the Orion Score — moderate business quality (68), weak growth (49), moderate balance-sheet safety (67) and rich valuation (23). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
67/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q4 2026 | ₹3,760.28 | ₹301.41 | 16.4% | ₹10.68 |
| Q3 2026 | ₹3,888 | ₹403.21 | 18.4% | ₹14.28 |
| Q2 2026 | ₹6,003.79 | ₹610.35 | 37.0% | ₹21.62 |
| Q1 2026 | ₹3,059.33 | ₹46.87 | 14.7% | ₹1.66 |
| Q4 2025 | ₹3,220.13 | ₹4.65 | 13.5% | ₹0.16 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2026 | ₹16,711.4 | ₹1,361.85 | ₹2,766.95 | 23.9% |
| FY 2025 | ₹13,145.84 | ₹1,047.1 | ₹2,092.28 | 14.2% |
| FY 2024 | ₹11,635.46 | ₹-1,501.67 | ₹1,183.27 | 5.4% |
| FY 2023 | ₹11,431.94 | ₹297.25 | ₹1,200.15 | 9.4% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| GLENMARK ★ | ₹61,130 Cr | 44.84 | 29.55% | 15.80% | 0.13x | 16.35% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹88,228 Cr | 25.64 | 12.55% | 9.93% | 0.21x | 15.11% |
| ASTERDM | ₹71,372 Cr | 108.60 | 8.93% | 10.07% | 0.46x | 13.98% |
| ABBOTINDIA | ₹59,615 Cr | 38.42 | 36.14% | 34.46% | 0.04x | 27.01% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹16,049.55 | ₹14,358.62 | ₹19,371.68 | ₹17,083.29 |
| Equity | ₹8,849.44 | ₹7,847.93 | ₹9,473.92 | ₹9,086.65 |
| Total Debt | ₹2,472.67 | ₹1,230.93 | ₹4,607.88 | ₹3,962.02 |
| Cash | ₹1,675.71 | ₹1,658.27 | ₹1,159.2 | ₹1,410.53 |
| Net Debt | ₹518.49 | — | ₹3,188.52 | ₹2,259.82 |
| Working Capital | ₹3,328.44 | ₹1,609.49 | ₹5,620.47 | ₹3,592.92 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 48.97% ↑ | 14.86% ↓ | 12.16% ↓ | 24.01% ↑ |
| Q3 FY2026 | 46.65% | 19.2% ↓ | 20.09% ↑ | 14.02% ↑ |
| Q2 FY2026 | 46.64% | 20.73% ↑ | 18.61% ↑ | 13.97% ↓ |
| Q1 FY2026 | 46.64% | 20.62% ↓ | 17.64% ↑ | 15.05% ↓ |
| Q4 FY2025 | 46.65% | 23.15% ↓ | 14.6% ↑ | 15.56% ↓ |
| Q3 FY2025 | 46.65% | 23.51% ↑ | 13.85% ↑ | 15.96% ↓ |
| Q2 FY2025 | 46.65% | 23.05% ↑ | 13.21% ↓ | 17.06% ↓ |
| Q1 FY2025 | 46.65% | 20.98% | 13.93% | 18.42% |
No recent corporate actions
Q4 FY2025
| Investor | Shares Held | Portfolio % | Change |
|---|---|---|---|
| norges-bank | — | — | — |
192 mutual fund schemes
Ask: "Is Glenmark Pharmaceuticals Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Glenmark Pharmaceuticals Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE935A01035. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.